The Epstein-Barr virus (EBV) is involved in the carcinogenesis of several human cancers such as nasopharyngeal carcinoma (NPC) and Burkitt lymphoma (BL). Given the consistent role of EBV in transformation and maintenance of malignant phenotype, antiviral strategies provide an attractive approach to target EBVexpressing cells. In that aim, we have tested the Cidofovir, which is an acyclic nucleoside phosphonate analog known to exert an antiproliferative activity in some human virusrelated tumors. Here, we show that Cidofovir induces a downregulation of the EBV oncoprotein LMP1 associated with a decrease of the antiapoptotic Bcl-2 and an increase of the proapoptotic Bax protein in Raji (BL) and C15 (NPC) cells. Using BL cell line BL2 B95-8 (BL2 infected with the B95.8 strain of EBV), we addressed the relation between EBV genome expression and modulation of viral oncoproteins by Cidofovir and/or ionizing radiation (IR). Cidofovir was able to significantly reduce LMP1 and EBNA2 mRNA and protein expression. This effect was associated with inhibition of proliferation, stimulation of apoptosis, and decrease of Bcl-2 expression in BL2 B95.8 cells. In addition, Cidofovir enhanced the radiationinduced apoptosis and the radiosensitivity through the proteolytic cleavage of death effectors caspase-9 and -3, which was specifically induced by combined treatment in EBV-positive cells compared to their negative counterparts. Furthermore, the combined treatment in nude mice led to a complete tumor remission without increasing toxicity in two human EBV-related cancer xenografts (Raji and C15). These results provide the basis for a novel anticancer strategy to enhance the therapeutic ratio of IR in EBV-related cancers.
Introduction
Epstein-Barr virus (EBV), a B-lymphotropic human herpes virus, is strongly associated with a number of cancer types including endemic Burkitt lymphoma (BL), nasopharyngeal carcinoma (NPC), and Hodgkin lymphoma (Weiss et al., 1989; Griffin et al., 2000) . The oncogenic potential of EBV in the etiology of these tumors is related to its ability to immortalize B lymphocytes. EBV infection of B lymphocytes in vitro and in vivo results in their transformation to immortalized lymphoblastoı¨d cell lines (LCL) that proliferate indefinitely and harbor the virus in the latent state (Kief, 1996) . Latent EBV infection is characterized by restricted expression of viral gene products, including six EpsteinBarr nuclear antigens (EBNAs), three membrane proteins (LMP1, LMP2A and LMP2B) and two small nonpolyadenylated nuclear RNAs (EBERs) (Kief, 1996) , which function cooperatively to initiate, maintain continuous proliferation, and probably prevent cell from undergoing terminal differentiation or apoptosis. Based on latent viral gene expression, three main types of latency have been characterized (Rowe et al., 1987) . In BL, the EBV-encoded latent protein expression is limited to EBNA1, termed latency type I. The intermediate latency type II (EBNA1+, LMP1+, and LMP2A+) occurs in NPC and Hodgkin's disease (Fahraeus et al., 1988; Shibata and Weiss, 1992) . The LCLs termed latency type III express the full spectrum of EBV latent proteins.
Increasing evidence indicates that some of these latent expressed viral oncoproteins are involved in the immortalization of host cells (Kief, 1996) . The role of EBNA2 is essential for initiation and maintenance of B-cell immortalization (Kempkes et al., 1995) . It has been shown that EBNA2 and EBNA leader protein (EBNA-LP) cooperate to induce the transition of the infected cells from G0 to G1 (Sinclair et al., 1994) . EBNA2 also activates the transcription of all viral proteins expressed in lymphoblastoid cell lines by transactivating: (i) the BamH1-C-promoter (Cp) (Sung et al., 1991) , from which transcription of all EBNA genes is controlled; (ii) the promoters of LMP1 and LMP2 (Abbot et al., 1990; Fahraeus et al., 1990) . Oncogenic potential of LMP1, frequently expressed in several EBV-associated cancers, is consistent with its ability to transform fibroblasts and to inhibit epithelial differentiation (Dawson et al., 1990) . In B cells, LMP1 confers a phenotype resembling activated lymphocytes, including induction of adhesion molecules, increased cell size, and entry into cell cycle (Wang et al., 1990) . Transforming properties of LMP1 are also related to its ability to activate signaling pathways, such as NF-kB, mitogen-activated protein kinases JNK and p38 (Eliopoulos et al., 1999) . Gene transfer studies demonstrated that the antiapoptotic effects of LMP1 in B cells are mediated by induction of antiapoptotic proteins Bcl-2, Mcl-1, and A20 Henderson et al., 1991; Laherty et al., 1992) .
The prospect to enhance apoptosis induced by ionizing radiation (IR), one of the most common therapeutic agents used for EBV-related cancers, may ultimately improve tumor control (Williams, 1991) . Identifying biological compounds that would restore the apoptotic pathway and enhance specifically the radiosensitivity of EBV-infected cells is hence a challenge to improve the therapeutic ratio in these types of cancers.
Given the critical role of viral oncoproteins in transformation and apoptosis, antiviral strategies would provide a means to repress viral oncoproteins. Indeed, antisense oligonucleotides against LMP1 or EBNA1 have been associated with inhibition of viral oncoprotein expression, induction of apoptosis, and sensitization of EBV-positive cells to cytotoxic agents (Roth et al., 1994; Kenney et al., 1998; Morgan et al., 2000) . However, antisense delivery remains extremely difficult to achieve in clinical applications, underlying the need for alternative approaches. Recently, some experimental studies reported that the antiviral agent Cidofovir [(S)-1-[3-hydroxy-2-phosphonyl methoxy propyl] cytosine], exhibited an antiproliferative effect in culture systems, animal models, against different viruse-related tumors (De Clercq et al., 1996; reviewed in Abdulkarim and Bourhis, 2001) . Cidofovir is converted by cellular kinases into its biologically active form (Balzarini et al., 1991) . In contrast to other antiviral agents, Cidofovir bypasses the first phosphorylation step by viral-encoded kinases, a rate-limiting step required for most other antiviral nucleosides (Pauwels et al., 1988) . We have previously shown that Cidofovir acts as a selective drug for human papillomaviruses (HPV)-infected cells to enhance in vitro and in vivo the radiosensitivity of cervical human carcinoma (Abdulkarim et al., 2002) . Other investigators showed the antiproliferative activity of Cidofovir against EBV-infected cells (Neyts et al., 1998; Johnson and Gangemi, 1999) . However, the mechanisms by which Cidofovir exerts this inhibitory effect remain unknown. In addition, the effect on EBV latent genes and the use of this drug in combination with IR in EBV-related cancers have not been investigated.
In this study, we show that Cidofovir, downregulates LMP1 and EBNA2 oncoproteins, with concomitant decrease of the antiapoptotic protein Bcl-2. The synergistic effect of Cidofovir and IR was selectively mediated by cleavage of caspase-9 and -3 and its downstream substrate poly(ADP-ribose) polymerase (PARP) in EBV-positive cells. For the first time, we provide evidence that an antiviral agent can efficiently restore the radiation-induced apoptosis and enhance the radiosensitivity both in vitro and in vivo, without increasing toxicity. These findings represent a novel therapeutic approach to target specifically EBV-positive cells and enhance the therapeutic ratio in EBV-related cancers.
Results

Cidofovir downregulates LMP1 oncoprotein in EBV-positive cells (Raji and C15)
The majority of type I BL, such as Raji cells tend to express all the known latency viral proteins and acquire many of the phenotypic characteristic of LCLs in vitro (Gregory et al., 1990) . The viral genes expressed in this situation generally include all EBNA and LMP. To determine whether Cidofovir could modulate the expression of viral oncoproteins LMP1 in Raji and NPC C15 cells, we performed immunoblotting after exposure to Cidofovir (10 mg/ml) for 24 and 48 h ( Figure 1a ). Densitometric analysis showed that the amount of LMP1 protein in Raji cells decreased by 60 and 85% at 24 and 48 h, respectively, compared to untreated tumors. Similarly, in C15 tumor cells, the amount of LMP1 protein decreased by 70 and 85% at 24 and 48 h, respectively (Figure 1b) .
Cidofovir downregulates the constitutive and the radiation-induced expression of viral oncoproteins in BL2 B95-8 cells EBV infection of originally negative BLs provides a valuable tool to study the effects of the antiviral agent on viral genes expression. With this aim, we used the Burkitt lymphoma BL2 parental cells and their EBV-positive counterparts BL2 B95-8 cells. Such infected cells, exhibit the type III phenotype as long as the virus integrity is maintained and express all EBV transformation-associated proteins (Murray et al., 1988) . Densitometric analysis revealed that the amount of LMP-1 protein in BL2 B95.8 cells decreased by 72% after Cidofovir exposure (10 mg/ml) (Figure 1c) . Expression of LMP-1 was at the threshold of detection when exposure to Cidofovir was prolonged up to 96 h (data not shown). The amount of EBNA2 protein in BL2 B95.8 cells also decreased by 44 and 66% at 10 and 100 mg/ml, respectively, compared to untreated cells (Figure 1c) . Surprisingly, LMP1 expression was enhanced twofold after exposure to IR (6 Gy/24 h), whereas EBNA2 expression was slightly increased after IR. Interestingly, the radiation-induced increase of LMP1 was abolished when cells were pretreated with Cidofovir ( Figure 1c ).
Cidofovir reduced LMP1 and EBNA2 mRNA expression
We performed real-time PCR to analyse LMP1 and EBNA2 mRNA levels in BL2 B95-8 cells after Cidofovir (10 and 100 mg/ml for 48 h), IR (6 Gy IR for 24 h), and combined treatment. The mRNA specie corresponding to LMP1 was reduced by 67% after Cidofovir at 10 mg/ ml for 48 h compared to untreated cells (Figure 2a ). In accordance with immunoblot analysis, LMP1 mRNA was increased by 66% after a dose of 6 Gy ( Figure 3a ). EBNA2 mRNA expression was reduced by 38% at 10 mg/ml for 48 h (Figure 2b ). Interestingly, radiationinduced increase of LMP1 mRNAs was suppressed when cells were pretreated with Cidofovir ( Figure 2a ).
Cidofovir-induced selective inhibition of proliferation in EBV+cancer cell lines
To analyse whether Cidofovir-mediated suppression of EBV oncoproteins could affect cell proliferation, both EBV-positive and -negative cell lines were exposed to increasing concentrations of Cidofovir (1-10-100 mg/ ml). As shown in Figure 3b , Cidofovir caused inhibition of cell proliferation in a dose-and time-dependent manner in Raji cells. At the concentration of 10 mg/ml, Cidofovir effectively inhibited the growth in Raji cells by 43, 74, and 91% at 3, 5, and 7 days respectively. Similar results were obtained in BL2 B95-8 cells exposed to Cidofovir (10-100 mg/ml) (Figure 3d ). In contrast to the antiproliferative effect of Cidofovir observed in EBVpositive cells, no significant growth inhibition occurred in two different EBV-negative cell lines (Ramos and BL2), even with higher concentrations of Cidofovir (Figure 3a, c) . These results indicate that the antiproliferative effect of Cidofovir is correlated to the EBV genome expression in malignant cells.
Cidofovir induces apoptosis and enhances the radiation-induced apoptosis of EBV-positive cancer cells in vitro
To investigate the mechanism involved in the inhibition of cell growth, the rate of apoptosis was evaluated by flow cytometry. The percentage of apoptosis in EBVinfected cells Raji and C15 was increased by three and twofold, respectively, after Cidofovir exposure compared to untreated cells (Figure 4b and data not shown). In contrast, Cidofovir exposure in EBV-negative cells did not trigger apoptosis ( Figure 4a ). To confirm the finding that Cidofovir-induced apoptosis in EBVpositive cancer cells, we also exposed BL2 cells and their EBV-positive counterparts BL2 B95.8 to two concentrations of Cidofovir (10 and 100 mg/ml) for 48 h. As shown in Figure 4 , panel c, BL2 cells treated with Cidofovir did not exhibit a significant increase of apoptotic rate compared to untreated cells. The percentage of sub-G1 peak in BL2 B95.8 treated with 10 and 100 mg/ml increased to three and fivefold, respectively, compared to untreated cells ( Figure 4 , panel d).
In Raji and C15, the combined treatment increased the apoptotic rate by twofold compared to antiviral alone or IR alone ( Figure 4b and data not shown). Similarly, as shown in Figure 4 , panel d, the apoptotic rate with combined treatment in BL2 B95.8 cells was greater than the percentage obtained with IR alone (threefold). In EBV-negative cells the sub-G1 peak was not increased by the combined treatment, compared to each treatment alone (Figure 4 , panel c). In contrast with BL2 B95.8 cells, which exhibited resistance to radiation-induced apoptosis (6 Gy), BL2 cells remain sensitive to radiation-induced apoptosis (30%) and show G2/M arrest in response to IR alone or combined treatment (Figure 4 , panel c). . Cells cultured with or without Cidofovir (10 mg/ml for 24 and 48 h) were harvested and analysed for LMP1 expression. LMP1 level was substantially decreased at 24 and 48 h in Raji and C15 cells treated with Cidofovir. Also, LMP1 and EBNA2 expression was assayed by Western blotting in BL2 B95.8 cells (c) treated by Cidofovir at two concentrations (10 and 100 mg/ml for 48 h), IR (6 Gy for 24 h), and the combined treatment. The blots were probed with monoclonal antibodies to LMP-1 and EBNA2. The amount of LMP1 and EBNA2 proteins was decreased at 10 and 100 mg/ml after Cidofovir exposure compared to untreated cells. IR enhances LMP1 and EBNA2 expression, whereas the combined treatment decreased the expression of both oncoproteins compared to Cidofovir alone
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Cidofovir induces a downregulation of Bcl-2 expression in EBV-positive cancers cells LMP1 has been implicated in the suppression of apoptosis of EBV-immortalized cells by upregulating several antiapoptotic cellular genes such as Bcl-2. Exposure of Raji cells to Cidofovir for 24 and 48 h induced a decrease of Bcl-2, compared to untreated cells ( Figure 5b ). In addition, BL2 B95.8 cells expressed Bcl-2 at a higher level than their EBV-negative counterpart. The amount of Bcl-2 in BL2 B95.8 cells was reduced by 40% with Cidofovir at 10 mg/ml ( Figure 5c ). IR did not induce a significant increase of Bcl-2 expression in BL2 B95.8 cells. However, we did not observe any additional effect when we combined Cidofovir to IR compared to Cidofovir alone. The expression of the proapoptotic protein Bax was analysed in Raji and BL2 B95.8 cells.
Immunoblotting analysis showed that Raji cells expressed Bax at a reduced level and this expression was slightly increased after Cidofovir exposure. In contrast, Bax was constitutively highly expressed in B12 B95.8 cells and this expression was not significantly altered after Cidofovir exposure (Figure 5d ). There was no significant effect of Cidofovir on Bcl-2 or Bax in EBVnegative cells (Figure 5a ).
Synergistic effect of Cidofovir and IR on caspase-9 and -3 cleavage in BL2 B95.8 cells
Proteolytic cleavage of caspase-9 and -3 generates active fragments with subsequent cleavage of downstream substrates in cells undergoing apoptosis (Green, 2000) .
To further explore the molecular basis of Cidofovirinduced apoptosis, we performed immunoblotting analysis to study caspase-9 and -3 activation. We also analysed the cleavage of PARP, the downstream substrate of caspase-3, in response to Cidofovir (10 mg/ ml for 12, 24, and 48 h) and/or IR (6 Gy) in BL2 and BL2 B95.8 cells.
In BL2 cells (Figure 6a) , the large active subunit of caspase-9 was detected after IR alone (6 Gy), whereas Cidofovir-treated cells exhibited only the procaspase-9 form at 47 kDa. Furthermore, the combination of Cidofovir and IR showed a similar pattern to IR alone. In contrast, in BL2 B95.8 cells, no detectable processing of procaspase-9 was observed after IR suggesting cellular resistance to irradiation-induced apoptosis in EBV-positive cells (Figure 6b ). We identified the p35 fragment generated by autoactivation of procaspase-9 in Cidofovir-treated cells (10 mg/ml for 12 and 24 h). A longer exposure (48 h) gave rise to both p37 and p35 proapoptotic fragments suggesting an amplification of the apoptotic signal in caspase activation cascade. Interestingly, a similar pattern was shown with Cidofovir exposure (12 and 24 h) combined with IR ( Figure 6b ).
To determine whether caspase-3, a downstream effector of caspase 9, is concomitantly required for Cidofovir-induced apoptosis in EBV-positive cells, we also studied caspase-3 cleavage by immunoblotting in BL2 cells and their EBV-positive counterparts. As shown in Figure 6c , BL2 cells failed to activate caspase-3 after Cidofovir exposure, but exhibited the processed active form after irradiation alone or with combined treatment. In contrast, in BL2 B95.8 cells caspase-3 cleavage was not detected after IR or Cidofovir exposure (10 mg/ml, 12 and 24 h). Interestingly, when Cidofovir was given prior to IR, caspase-3 cleavage product (p17) was detected, suggesting a synergistic effect on caspase-3 activation. Moreover, caspase-3 cleavage was also induced in Cidofovir-treated cells for 48 h (Figure 6d ).
In accordance with caspase-9 and -3 processing, the fragment corresponding to PARP apoptotic product (86 kDa) was detected in irradiated BL2 cells alone (Figure 6e ), whereas the apoptotic fragment was detected in BL2 B95.8 cells exposed to Cidofovir for Figure 2 Cidofovir reduced the constitutive and the radiationinduced LMP1 and EBNA2 mRNA level in BL2 B95.8 cells. Realtime quantitative RT-PCR was performed using gene-specific, fluorogenic probes and the Universal MasterMix kit as described in the Materials and methods. RT-PCR of LMP1 (a) and EBNA2 mRNA (b) from BL2 B95.8 cells was performed after exposure to Cidofovir (10 and 100 mg/ml for 48 h), IR (6 Gy for 24 h), and the combined treatment. Quantification of the mRNA level was performed after normalization for b2-microglobulin mRNA in different conditions. All samples were run as triplicates and the values are reported as the relative level over untreated cells. BL2 EBV-negative cell line was used as a negative control.
48 h or to the combined treatment (Figure 6f ). Equal loading was checked by actin immunobloting in Figure 6g . Altogether, our data demonstrate that the radiosensitizing effect of Cidofovir is at least mediated by activation of apoptotic mitochondrial pathway in EBV-positive cells.
Cidofovir enhances radiosensitivity in EBV-positive cancer cells in vitro
We performed a colony-forming assay in order to determine whether Cidofovir could modulate radiosensitivity. The dose of Cidofovir used corresponded to the IC 5 and IC 10 of Cidofovir. A strong effect of Cidofovir on radiation-induced clonogenic cell death was observed in EBV-positive cells. This effect was seen at doses of irradiation as low as 1 Gy in Raji cells (Figure 7a ). The surviving fraction at 2 Gy (SF2) was markedly reduced with combined treatment compared to irradiation alone (4.4 vs 51% for Raji and 10 vs 64% for BL2 B95.8 cells) (Figure 7a, c) . In contrast, in EBVnegative cells lines, the combined treatment generated only minor changes in clonogenic survival compared to irradiation alone and this effect was not enhanced at a higher irradiation dose (4 Gy) (Figure 7b, d ). Figure 8 . In nude mice bearing Raji xenografts (Figure 8a) , the mean tumor volume increased by 680% within 28 days in saline-treated control group. A moderate inhibition of tumor growth was found with Cidofovir or radiotherapy alone. In contrast, combining Cidofovir and IR produced a statistically significant tumor growth delay in Raji xenografts (Po0.001) and the tumors regressed by 57%. In C15 xenografts (Figure 8b ), the mean tumor volume increased by 565% within 26 days in salinetreated group. In the groups treated with Cidofovir or irradiation alone, the mean tumor volume increased by 345 and 170%, respectively. In contrast, when Cidofovir and irradiation were combined, the tumors regressed by 86% during the same period. The systemic administration of the drug (100 mg/kg subcutaneously, daily for 5 days) produced a comparable effect on tumor growth as compared to intratumoral injection (60 mg/kg daily, for 5 days) (Figure 8b) . Importantly, 60% of the mice were found to be in complete remission within 5 weeks in the combined group and survived up to 6 months for the two cell lines Raji and C15. Interestingly, no difference in normal tissue reactions (skin) was seen in mice treated with Cidofovir and irradiation.
Discussion
The consistent role of EBV in transformation and maintenance of malignant phenotype in certain tumors suggests that EBV-based strategies could be used to treat such tumors. So far, few investigators have reported antiviral-based strategies to target EBV cancers cells. Two approaches have been used: (i) antisense oligonucleotides have been demonstrated to inhibit viral oncoprotein expression such as LMP1 or EBNA1, resulting in cell proliferation decrease and enhanced sensitivity to chemotherapeutic agents in vitro (Roth et al., 1994; Kenney et al., 1998; Morgan et al., 2000) . (ii) A second approach used sodium butyrate (Chung et al., 2000) or IR (Westphal et al., 2000) in combination with Ganciclovir. Sodium butyrate or IR have the ability to convert the latent form of EBV infection normally found in tumor cells into the lytic form, and enhance the sensitivity of EBV tumor cells to the cytotoxic effects of Ganciclovir.
In this study, we report for the first time the effects of Cidofovir on viral oncoproteins expression, apoptosis, and radiosensitivity in EBV-related human cancers. We showed that Cidofovir alone was able to inhibit latent viral gene expression involved in transformation, such as LMP1 and EBNA2. This effect was correlated with EBV genome expression and associated with a decreased level of Bcl-2 protein and induction of apoptosis in BL and NPC cell lines. The mechanism underlying apoptosis involved proteolytic cleavage of death effectors caspase-9 and -3 specifically induced by combined treatment in EBV-positive cancers cells. These biochemical events were associated with increase of radiation-induced apoptosis and enhanced radiosensitivity in vitro and in vivo.
The frequent expression of LMP1 in tumor biopsies from EBV-positive human cancers such as Hodgkin's disease, immunoblastic lymphomas and NPC suggests that it may contribute to EBV-mediated oncogenesis. The oncogenic ability of LMP1 can be attributed to cell death suppression by a variety of stimuli through upregulation of antiapoptotic proteins such as Bcl-2, Mcl-1 A20, and cAIPs Henderson et al., 1991; D'Souza B et al., 2000; Hong et al., 2000) . Given the well-established role of LMP-1 in EBVrelated malignancies, we investigated whether Cidofovir could alter its expression. Here, we show that LMP-1 expression was decreased after Cidofovir exposure in NPC C15 and BL Raji cells. To address the relation between viral genome expression and Cidofovir or IR effect, we used latency type III BL2 Burkitt lymphoma cells infected with B95.8 strain of EBV. The latency type III cells express all EBV transformation-associated proteins and are not generally permissive for virus replication (Murray et al., 1988) . Thus, BL2 B95.8 cells constitute a powerful tool to study the modulation of viral oncoprotein expression without interfering with the EBV lytic cycle. In addition to LMP1, EBNA2 expression was decreased after Cidofovir exposure at the transcriptional level in BL2 B95.8 cells. The functional importance of EBNA2 is related to its role as a viral transactivator, which upregulates LMP1 transcription in B lymphocytes (Wang et al., 1990) . The LMP1 mRNA downregulation could hence be a direct consequence of EBNA2 reduction by Cidofovir. Another mechanism could involve inhibition of viral DNA polymerases (Balzarini et al., 1991) with subsequent alteration of latent EBV genes expression. We previously reported that Cidofovir downregulates HPV E6 and E7 viral oncoproteins at the transcriptional level, with subsequent reactivation of tumor suppressor genes p53 and pRb. This effect was associated with the reduction of HPV transcripts in cervical carcinoma (Abdulkarim et al., 2002) . The reduction of LMP1 and EBNA2 oncoproteins in EBV cancer cells could be a consequence of EBV transcripts decrease. The immediate early response of mammalian cells to ionizing radiation includes activation of transcription factors, such as AP-1, p53, and NF-kB (Weichselbaum et al., 1994; Prasad et al., 1995) . LMP-1 acts constitutively like active tumor necrosis factor (TNF) receptor family (Eliopoulos and Rickinson, 1998; Eliopoulos et al., 1999) and activates NF-kB in EBV-related malignancies. To date, the modulation of LMP1 expression after IR in EBVrelated cancers has not been studied. Interestingly, IR a commonly used treatment in many EBV-related cancers (NPC and Hodgkin disease), increased LMP1 expression, and this upregulation was observed even with low doses in the range of those used for clinical purposes. The resistance to radiation-induced apotosis in EBV tumor cells could be because of the emergence of radioresistant clones expressing high levels of LMP1 associated with NF-kB activation. Whether activation of NF-kB by IR is directly related to upregulation of LMP-1 needs to be further investigated. , d) , the large subunit of PARP and the active subunits resulting from their cleavage (e, f) was detected using polyclonal rabbit anticaspase-9 (Cell Signaling Technology) anticaspase-3 (CPP-32, Pharmingen), monoclonal anti-PARP (Clone Ab2, Oncogene research products), respectively, in BL2 and BL2 B95.8 cells for the indicated treatments. In BL2 cells, we detect the cleaved products of caspase-9 (a) caspase-3 and (c) PARP in response to IR. In contrast, cleaved fragments were undetectable in irradiated BL2 B95.8 cells (b, d, f) . Caspase activation was restored after Cidofovir (48 h) or combined treatment in BL2 B95.8 cells. For comparison, expression of actin in the same extracts was measured (g, h)
It has been reported that tumorigenicity in EBVpositive BL cells correlates with an increased expression of the antiapoptotic protein Bcl-2 and resistance to apoptosis (Komano et al., 1998) . EBV infection confers resistance to apoptosis by upregulation of Bcl-2 expression, even in the absence of LMP-1 and BHRF1 expression, both of which are known to have antiapoptotic function.
In this paper, we attempted to establish the correlation between EBV infection and the susceptibility to apoptosis induced by Cidofovir and/or IR. We find that apoptosis is differentially triggered by Cidofovir and/or IR, depending on the EBV status of the cell lines studied. Indeed, the EBV-negative BL cell line BL2 is very sensitive to IR-induced apoptosis (Figure 4) , expresses Bcl-2 at low level ( Figure 5 ) and shows activation of caspase-9 and -3 ( Figure 6 ). The pattern of these apoptotic markers is completely reversed by EBV infection of irradiated BL2 cells (Figure 5c) . A similar mechanism of resistance to apoptosis was recently reported in response to Fludarabine, a cytotoxic agent used in hematological malignancies (Fagard et al., 2002) . Our data strongly support the notion that an antiviral agent is able to decrease the apoptotic B95.8, and (d) BL2 cell lines were treated with either no drug or cidofovir (5 and 10 mg/ml) for 24 h. Cells were resuspended in fresh medium before plating them into culture dishes and irradiated by a single dose of radiation. The surviving fraction was normalized against the surviving fraction of untreated cells. After 10-14 days, the number of colonies (>50 cells) was scored. Points represent the mean of two separate experiments7s.e.m., performed in triplicate, (e) shows clonogenic cells of BL2 B95.8 treated with Cidofovir and/ or IR. As shown, the combined treatment enhances the radiosensitivity by increasing clonogenic cell death threshold in EBV-positive BL2 B95.8 cells through antiapoptotic protein Bcl-2 decrease. This modulation is likely sufficient to restore radiation-induced apoptosis in response to combined treatment by promoting the intrinsic mitochondrial pathway.
In our model, the survival or cell death in response to Cidofovir and/or IR does not seem to be dependent on the p53 target gene, Bax protein level. These findings could be related to p53 status, which is inactivated in both cell lines (Fagard et al., 2002) , suggesting that Bcl-2 modulation is predominant within Bcl-2/Bax ratio.
Based on these findings, we propose a model wherein the sensitizing effect of Cidofovir is likely mediated by reduction of viral oncoprotein LMP-1 and antiapoptotic protein Bcl-2 levels, which presumably triggers activation of the intrinsic pathway through caspases cleavage in EBV-positive cells.
We report for the first time that inhibition of viral oncoproteins expressed during the latency phase of EBV was associated with a marked increase of radiosensitivity in vitro (Figure 7 ) and in vivo (Figure 8 ). The role of EBV in tumorigenesis has been fully investigated. Using Cidofovir, we were able to target some molecular effectors involved in EBV oncogenesis. This approach by (i) reducing viral oncoproteins, (ii) inhibiting proliferation, and (iii) increasing apoptosis could explain the increasing radiosensitivity in vitro and the marked tumor growth delay obtained with combined treatment in vivo. The combination of Cidofovir and IR appears to be a promising strategy to improve therapeutic outcomes in EBV-associated cancers. Our study provides the rationale to evaluate a novel and feasible approach in clinical applications.
Materials and methods
Cell lines
Two EBV+ human cancer cell lines were used: a typical nasopharyngeal carcinoma, C15, kindly provided by Busson et al. (1988) and the BL Raji. The BL Ramos (EBV negative) was used as negative control for viral infection. Raji and Ramos cells were maintained in RPMI 1640, with 10% heatinactivated fetal bovine serum (FBS) supplemented with penicillin/streptomycin and 2 mm glutamine at 371C in 5% CO2. The BL cell lines EBV-negative BL2 cells and EBVpositive BL2 B95-8 cells were maintained in RPMI 1640, supplemented with 10% of FCS. BL2 B95.8 cells were converted to EBV positive status in vitro through repetitive infection of BL2 cells with the EBV B95.8 strain (Klein et al., 1975) . These infected cells express all EBV growth and transformation-associated proteins and are not generally permissive for virus replication (Murray et al., 1988) .
Antiviral compound
Cidofovir (HPMPC) was obtained from Pharmacia Upjohn (Les Yvelines, France). The half-life of this compound is 48 h in vitro. To keep stable concentration of Cidofovir in tissue culture medium, we added this drug three times per week. The cell lines were treated with various doses of Cidofovir (1-10 mg/ ml) for 1 and 2 days. Cells were harvested, washed in PBS and lysed for protein extraction.
Tumor xenografts irradiation
During irradiation, mice were immobilized, and the entire body was shielded with lead, except for the tumor site in the flank of the mice. Irradiation was delivered using a RT 250 Philips (0.69 Gy/min) under a tension of 200 kV, 200 mA.
Immunoblot analysis
Cells were washed with PBS, and lysed in lysis buffer containing Nonidet P-40 for 30 min on ice. Cell debris were removed by centrifugation and protein concentration was determined by Bio-Rad protein assay (Biorad). Equal amounts of proteins were boiled for 5 min in SDS sample buffer (40 mm Tris-HCl, pH 7.4, 5% glycerol, 5% mercaptoethanol, 2% SDS, 0.05% bromophenol blue) and subjected to SDSpolyacrylamide gel electrophoresis. The proteins were electrotransfered to nitrocellulose membranes (Hybond, Biorad laboratories, Hercules, CA, USA) and blocked overnight at 41C in PBS, 0.1% Tween, containing 5% nonfat dried milk. The viral oncoprotein LMP1 was detected by immunoblotting with a monoclonal anti-LMP1 antibody (clone CS1, CS2, CS3 and CS4 cocktail) and EBNA2 (clone E8.26, Oncogene). The following antibodies were used: anti-Bcl-2 (clone 100, Santa Cruz Biotechnology), and anti-Bax (clone B-9, Santa Cruz Biotechnology), polyclonal rabbit anticaspase-3 (CPP-32, Pharmingen), polyclonal rabbit anticaspase-9 (Cell Signaling Technology), and monoclonal anti-PARP (clone Ab-2, Oncogene research products). Filters were developed using enhanced chemiluminescence ECL system (BioRad). Anti-bactin (clone AC-40, Sigma) was used to control protein loading. The densitometric analysis of the bands was performed using MAC BAS software.
TaqMan real-time RT-PCR
Total RNAs from the cell clone cultures were prepared using the SV Total RNA isolation system (Promega, Madison, WI, USA) followed by DNase I treatment. Reverse transcription was performed using the Superscript II with random hexamers according to the manufacturer's protocol (Stratagene, Cedar Creek, TX, USA). Real-time quantification was performed using gene-specific, fluorogenic probes and the Universal MasterMix kit (PE-Applied Biosystem, Warrington, UK) in a final volume of 25 ml. The reaction mixture contains all primers at 900 nm and the probe at 200 nm. A two-step PCR procedure of 15 s at 951C and 60 s at 601C was applied for 40 cycles. PCR and TaqMant analyses were performed using the ABI/PRISM 5700 sequence detector system (PE Applied Biosystems). The PCR reactions were performed using FAM-labelled GAPDH and b2-microglobulin Mix (PEApplied Biosystem), EBNA2 and LMP1 probes. The oligonucleotides sequences were as follows: EBNA2: forward primer CCTGGACACAAGAGCCATCA; reverse primer TCCAAAGCATTCGCATAGCA and probe CTA-GAGGTCCATGCCCGACGTCATATCCTA. LMP1: forward primer TCCTCCTGTTTCTGGCGATT, reverse primer GGAGTCATCGTGGTGGTGTTC, and probe CACTGTGTCGTTGTCCATGGTAATACATCCA. Standard curves of cDNAs from the cell clones were used to calibrate C T to amounts of test and normalizing cDNAs on each 96-well plate run. Normalized values for mRNA expression were calculated as (100 Â test mean)/(normalizer mean). All samples were run as triplicates.
DNA content analysis by propidium iodide (PI) staining
Flow cytometry analysis of PI-stained cells was performed to demonstrate the effect of Cidofovir and/or IR on cell cycle progression and apoptosis. Briefly, 1 Â 10 6 cells were cultured without or with 5 and 10 mg/ml of Cidofovir, 24 h later cells were irradiated with 3 and 6 Gy and collected 12 and 24 h after irradiation. Cells were harvested at different times, washed, and fixed in 70% ethanol overnight at 41C. Before flow cytometry analysis, cells were washed and stained with 1 ml of PI (15 mg/ml) containing 2.5 mg/ml RNase. DNA content was determined by a FACScan flow cytometer (Becton Dickinson) and the percentage of apoptotic cells (sub-G1 peak) was determined by CellQuest software.
Cellular proliferation and clonogenic survival assays
To study the inhibitory effect of Cidofovir on cell growth, Raji and Ramos cells (10 5 /ml) were incubated with various concentrations of Cidofovir (1, 10, 50, and 100 mg/ml) for 3, 5, and 7 days in 96-well plates. After culture, cell number and viability were evaluated by staining with Trypan blue and counting using light microscopy.
To evaluate cell killing on EBV-positive and -negative cells, colony-forming assay was performed by plating the appropriate number of cells into culture dishes in triplicate. Exponentially growing cells were incubated with cytostatic concentration of Cidofovir (1, 5, and 10 mg/ml) for 24 h. The cells were resuspended in fresh medium before plating them into culture dishes and the dishes were irradiated. The cells were irradiated (0-4 Gy) at room temperature, with a 137 Cs g-rays source at a dose rate of 1.45 Gy/min. After 10-14 days, the number of colonies (>50 cells) was scored. Semiliquid methylcellulose was used and the surviving fraction was normalized to the surviving fraction of untreated cells.
Growth of human tumor xenografts in vivo and experimental design
Female swiss nu/nu mice were fed ad libitum with irradiated food (UAR, Villemoisson, France) and filtered water (no 86/ 609/CEE of the European Community). In all 3 Â 10 6 cells were injected subcutaneously (s.c.) into the flank of animals aged between 6 and 8 weeks Mice bearing 120-520 mm 3 tumors were used for in vivo experiments. At day 0, tumor volume was determined by direct measurement, calculated by the formula (D Â d 2 Â 1/2). Mice were randomly assigned to treatment groups (6-8 in each group) and tumor volume was measured twice a week for at least 40 days.
To study the effect of combining Cidofovir and irradiation, animals were assigned in four groups in C15 and Raji xenografts: (1) Control group received PBS, (2) Cidofovir (100 mg/kg, days 1-5), (3) irradiation (7 Gy on days 3 and 5), and (4) combined group receiving Cidofovir (100 mg/kg, days 1-5) and irradiation (7 Gy on days 3 and 5). For C15 tumors, Cidofovir was injected intratumorally (60 mg/kg, days 1-5) or s.c. in the neck (100 mg/kg, days 1-5). For Raji xenografts, Cidofovir was given intraperitoneal (i.p.) (100 mg/kg, daily). The nephrotoxicity was prevented by probenecid i.p. administration before Cidofovir.
Statistical analysis
In vivo data are reported as the percentage of original (day 0) tumor volume and plotted as fractional tumor volume7s.e.m. Statistical significance was determined by Kruskal-Wallis and Mann-Withney U-tests.
